MYGN - Earnings announcements

SALT LAKE CITY, April 28, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter of 2026. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registe

Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and ad

SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2025. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please reg

Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million.Entered a strategic collaboration with SOPHiA GENETICS (NASDAQ:SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) te

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering,

Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-over-year, benefiting from product mix, improving average revenue per test trends, and greater laboratory efficiencies. Second quarter 2025 GAAP net loss of $330.5 million, or $(3.57) per share, reflecting non-cash impairment charges

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registerin

Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag

SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a

Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a d

Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improved significantly from $55 million and $(19) million, respectively, in the first quarter of 2023.First quarter GAAP earnings per share and adjusted earnings per share of $(0.29) and $(0.01), respectively, improved significantly as compared to $(0.67) and $(0.21), respectively, in the first quarter of 20

SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company's quarterly earnings will be released the same day after the market closes.   During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To par

SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes.  During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2023.   Conference Call and Webcast The dial-in number for domestic callers is 1-800-771-6781. International callers may dial 1-212-231-2900. All callers will be asked to reference reservation number 22028316. An archived replay

SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the period ending June 30, 2023. Conference Call and WebcastThe dial-in number for domestic callers is 1-800-954-0653. International callers may dial 1-212-231-2921. All callers will be asked to reference reservation number 22027563. An archived rep

Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer test volumes grew 24% year-over-year, the second consecutive quarter of double-digit growth year-over-year.Hereditary cancer test volumes in Women's Health grew 32% year-over-year.GeneSight® pharmacogenomics test volumes grew 31% year-over-year and 15% sequentially from the previous quarter.Prenatal test volumes grew 12% year-over-year, excluding contributions from the SneakPeek Early Gender DNA Test. Diluted GAAP earnings per share (EPS) were $(0.67) and adjusted EPS were $(0.21) in the first qu

SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Wednesday May 3, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the period ending March 31, 2023. Conference Call and WebcastThe dial-in number for domestic callers is 1-800-582-4086. International callers may dial 1-212-231-2905. All callers will be asked to reference reservation number 22026701. An archived rep

Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender DNA Test. GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022.Gross margin for the fourth quarter was approximately 70% reflecting underlying price stability and disciplined cost management.Diluted GAAP earnings per share (EPS) were $(0.52) and adjusted EPS were $(0.12) in the fourth quarter of 2022.Issued fiscal first quarter and full year 2023 financial guidance. SALT LAKE CITY, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leade

SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on Tuesday, Feb. 28, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the period ending Dec. 31, 2022. The dial-in number for domestic callers is 1-800-920-6941. International callers may dial 1-212-231-2939. All callers will be asked to reference reservation number 22025948. An archived replay of the call will be

Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 million), change of estimates1 ($5.3 million). Third quarter testing volumes, excluding divested businesses, grew 12% year-over-year. Hereditary cancer testing volume continued to improve in 2022 and grew 4% year-over-year in the third quarter. GeneSight volumes grew 34% over third quarter of 2021.We believe that the underlying pricing of Myriad testing products remains stable, notwithstanding that average selling price overall was negatively impacted by currency translations, change of estimates

SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and chief executive officer, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad's performance for the period ending Sept. 30, 2022. The dial-in number for domestic callers is 1-800-954-0689. International callers may dial 1-21

Highlights:  Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022 Diluted GAAP earnings per share (EPS) of $(0.18) and adjusted EPS of $0.04 in the second quarter of 2022Fiscal year 2022 financial guidance updated to reflect additional $20 million investment in research and development, technology, and sales and marketing programsEnded the quarter with $283.6 million in cash, cash equivalents and investments SALT LAKE CITY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today

SALT LAKE CITY, July 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Aug. 4, 2022 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and chief executive officer, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad's performance for the period ending June 30, 2022. The dial-in number for domestic callers is 1-800-918-9482. International callers may dial 1-

Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03 year-over-year, respectivelyEnded the quarter with $339.2 million in cash, cash equivalents and investmentsNew partnership with Intermountain Precision Genomics to launch Precise™ Liquid Biopsy Therapy Selection Test SALT LAKE CITY, May 05, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today ann

SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad's performance for the period ending March 31, 2022. The dial-in number for domestic callers is 1-800-954-0620. International callers may dial 1-212-231-2920. A

Highlights: Strong business performance despite COVID-19 headwindsRevenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively Excluding revenue from divested businesses, revenue increased 19% for the fourth quarter and 34% for the year Diluted GAAP earnings per share (EPS) of $(0.10) and adjusted EPS of $(0.02) in the fourth quarter of 2021Ended the quarter with $398.8 million in cash, cash equivalents and investments SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its fourth quarter and year

SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on Thursday, February 24, 2022 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad's performance for the period ending December 31, 2021. The dial-in number for domestic callers is 1-800-926-5188. International callers may dial 1-212-231-2901. All callers will be asked to refer

Highlights: Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue increased 27% year-over-yearDiluted GAAP earnings per share (EPS) of $0.30 and adjusted EPS of $(0.02) SALT LAKE CITY, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2021 and provided an update on recent business performance and strategic transformation plans.   "We are encouraged by our third quarter performance, and the execution of our teammates on our strategic growth and transformation plans that resulted in year-over-yea

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesday, November 2, 2021. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics' performance for the third quarter of 2021. The dial-in number for domestic callers is 1-800-920-2776. International callers may dial

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans.  "This was another solid quarter for Myriad Genetics as we delivered strong revenue growth and grew earnings ahead of our initial expectations, an important step towards demonstrating our ability to achieve our goal of sustainable long-term growth and profitability," said Paul J. Diaz, president and CEO. "These results reflect the hard work of our teammates, and their dedication to me

SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, August 3, 2021. The company's quarterly earnings will be released prior to the market opening on August 3, 2021. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics' performance for the second quarter of 2021. The dial-in number for domestic callers is 1-800-920-2191. International callers may dial